Bupropion in the Treatment of Methamphetamine Dependence

• Status: Completed
• Trial end date: 2011-05-20
• Target enrollment: 0
• Participant gender: All

Summary

Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Treatments: Bupropion; Methamphetamine

Criteria

Inclusion Criteria:

• patient in the substance use disorder program at either the Omaha VA Medical Center or at Catholic Charities Campus for Hope

• diagnosis of methamphetamine dependence as well as presence or history of psychosis based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria (not to include patients in full sustained remission)

• provide names, addresses, and phone numbers of at least two collateral informants who can provide information on their methamphetamine and other drug use during follow-up

• must sign an informed consent as approved by the UNMC Internal Review Board (IRB) and Catholic Charities Research Committee.

Exclusion Criteria:

• a history of severe injury to their brain

• advanced cardiac, pulmonary, renal or liver disease

• predisposition to seizures

• history of bulimia or anorexia nervosa

• current diagnosis of major depressive disorder

• diagnosis or past history of panic disorders, schizophrenia, or bipolar affective disorder

• family history or childhood history of epilepsy or seizures

• history of strokes, brain tumors, or bleeding in the brain.

• used any psychoactive drug within one week of study entry (two weeks for MAO (monoamine oxidase) inhibitors or protriptyline, four weeks for fluoxetine)

• currently using any theophylline product (e.g. Theodur)

• used an investigational drug in any study within the past four weeks

• used a therapeutic course of bupropion SR for > 1 week at any time in the past 12 months or have been evaluated in previous studies examining bupropion SR at anytime

• If female, the participant must not be pregnant or breast feeding